ArticleNature biomedical engineering2022
Biomaterial vaccines capturing pathogen-associated molecular patterns protect against bacterial infections and septic shock.
Article in Nature biomedical engineering, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.
- Research progress on T-cell responses inFrontiers in microbiology · 2026Pooled it
- RpoE-mediated virulence attenuation elicits protective immunity in hypervirulentEmerging microbes & infections · 2026Article
- Nano-kinetic implant surface mediates osteo-antibacterial synergy through electromagnetic-mechanical coupling.Nature communications · 2026Article
- DAMPs, PAMPs, and Alarmins: From Mechanism to Therapy.MedComm · 2026Review
- Kinetics of molecular patterns captured by mannose-binding lectin in septic shock correlate with clinical outcome: a monocentric prospective observational study.Intensive care medicine experimental · 2025Article
- Scaffold vaccination for prevention of orthopedic device infection.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- A Tailored Artificial Biocatalyst for Bacterial Endophthalmitis Therapy via Enhanced Ferroptosis-Like Death.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Immunoengineering: An Emerging Field in Infectious Diseases.The Journal of infectious diseases · 2025Review
- Biocompatible cloaking of bacteria for effective tumor imaging and therapy.Materials today. Bio · 2025Article
- Cell-Instructive Biomaterials with Native-Like Biochemical Complexity.Annual review of biomedical engineering · 2025Review
- Synthetic Biology-Based Engineering Cells for Drug Delivery.Exploration (Beijing, China) · 2025Review
- A polyvalent vaccine for selectively killing tumor-associated bacteria to prevent cancer metastasis.Science advances · 2025Article
- Chiral polypeptide hydrogels regulating local immune microenvironment and anti-tumor immune response.Nature communications · 2025Article
- Cytokine-overexpressing dendritic cells for cancer immunotherapy.Experimental & molecular medicine · 2024Review
- Transformable Gel-to-Nanovaccine Enhances Cancer Immunotherapy via Metronomic-Like Immunomodulation and Collagen-Mediated Paracortex Delivery.Advanced materials (Deerfield Beach, Fla.) · 2024Article
- Advances in antibacterial activity of zinc oxide nanoparticles againstBiomedical reports · 2024Review
- Durable lymph-node expansion is associated with the efficacy of therapeutic vaccination.Nature biomedical engineering · 2024Article
- Recent Review on Biological Barriers and Host-Material Interfaces in Precision Drug Delivery: Advancement in Biomaterial Engineering for Better Treatment Therapies.Pharmaceutics · 2024Review
- Transdermal microarrayed electroporation for enhanced cancer immunotherapy based on DNA vaccination.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- In Situ Hydrogel Modulates cDC1-Based Antigen Presentation and Cancer Stemness to Enhance Cancer Vaccine Efficiency.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 2 institutions in 1 country.
Funding
Abstract
Most bacterial vaccines work for a subset of bacterial strains or require the modification of the antigen or isolation of the pathogen before vaccine development. Here we report injectable biomaterial vaccines that trigger potent humoral and T-cell responses to bacterial antigens by recruiting, reprogramming and releasing dendritic cells. The vaccines are assembled from regulatorily approved products and consist of a scaffold with absorbed granulocyte-macrophage colony-stimulating factor and CpG-rich oligonucleotides incorporating superparamagnetic microbeads coated with the broad-spectrum opsonin Fc-mannose-binding lectin for the magnetic capture of pathogen-associated molecular patterns from inactivated bacterial-cell-wall lysates. The vaccines protect mice against skin infection with methicillin-resistant Staphylococcus aureus, mice and pigs against septic shock from a lethal Escherichia coli challenge and, when loaded with pathogen-associated molecular patterns isolated from infected animals, uninfected animals against a challenge with different E. coli serotypes. The strong immunogenicity and low incidence of adverse events, a modular manufacturing process, and the use of components compatible with current good manufacturing practice could make this vaccine technology suitable for responding to bacterial pandemics and biothreats.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.